Hims & Hers vs Veeva Systems

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (86 vs 86)
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile
Veeva Systems logo

Veeva Systems

LeaderHealthcare Tech

Life Sciences Cloud

Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.

AI VisibilityBeta
Overall Score
A86
Category Rank
#9 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
88
Gemini
90

About

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.

Full profile

AI Visibility Head-to-Head

86
Overall Score
86
#8
Category Rank
#9
79
AI Consensus
78
stable
Trend
stable
88
ChatGPT
84
92
Perplexity
88
83
Gemini
90
90
Claude
92
89
Grok
84

Key Details

Category
Telehealth Pharmacy
Life Sciences Cloud
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Hims & Hers
Telehealth Pharmacy
Only Veeva Systems
Life Sciences Cloud

Integrations

Only Veeva Systems
Veeva Systems is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.